Literature DB >> 26313421

Resistance to EGFR-targeted therapy by Ets-1 inactivation.

Osamu Tetsu1,2, David W Eisele1,2, Frank McCormick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26313421      PMCID： PMC4825599          DOI： 10.1080/15384101.2015.1086200

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

3.  Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.

Authors:  Jayne M Stommel; Alec C Kimmelman; Haoqiang Ying; Roustem Nabioullin; Aditya H Ponugoti; Ruprecht Wiedemeyer; Alexander H Stegh; James E Bradner; Keith L Ligon; Cameron Brennan; Lynda Chin; Ronald A DePinho
Journal:  Science       Date:  2007-09-13       Impact factor: 47.728

4.  EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Authors:  Janyaporn Phuchareon; Frank McCormick; David W Eisele; Osamu Tetsu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

5.  Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Authors:  Dalia Ercan; Chunxiao Xu; Masahiko Yanagita; Calixte S Monast; Christine A Pratilas; Joan Montero; Mohit Butaney; Takeshi Shimamura; Lynette Sholl; Elena V Ivanova; Madhavi Tadi; Andrew Rogers; Claire Repellin; Marzia Capelletti; Ophélia Maertens; Eva M Goetz; Anthony Letai; Levi A Garraway; Matthew J Lazzara; Neal Rosen; Nathanael S Gray; Kwok-Kin Wong; Pasi A Jänne
Journal:  Cancer Discov       Date:  2012-09-07       Impact factor: 39.397

6.  Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor.

Authors:  A G Batzer; D Rotin; J M Ureña; E Y Skolnik; J Schlessinger
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272
  6 in total
  3 in total

Review 1.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 2.  ETS-targeted therapy: can it substitute for MEK inhibitors?

Authors:  Osamu Tetsu; Frank McCormick
Journal:  Clin Transl Med       Date:  2017-05-02

3.  Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.

Authors:  Julia Schueler; Cordula Tschuch; Kerstin Klingner; Daniel Bug; Anne-Lise Peille; Leanne de Koning; Eva Oswald; Hagen Klett; Wolfgang Sommergruber
Journal:  Cells       Date:  2019-07-18       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.